These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 35126102)

  • 1. Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries.
    Blonda A; Barcina Lacosta T; Toumi M; Simoens S
    Front Pharmacol; 2021; 12():750742. PubMed ID: 35126102
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
    Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
    Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments.
    Dangouloff T; Botty C; Beaudart C; Servais L; Hiligsmann M
    Orphanet J Rare Dis; 2021 Jan; 16(1):47. PubMed ID: 33485382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of gene-based therapies for patients with spinal muscular atrophy type I in Australia.
    Wang T; Scuffham P; Byrnes J; Downes M
    J Neurol; 2022 Dec; 269(12):6544-6554. PubMed ID: 35980467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER).
    Dean R; Jensen I; Cyr P; Miller B; Maru B; Sproule DM; Feltner DE; Wiesner T; Malone DC; Bischof M; Toro W; Dabbous O
    J Mark Access Health Policy; 2021 Feb; 9(1):1889841. PubMed ID: 33708361
    [No Abstract]   [Full Text] [Related]  

  • 6. Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios.
    Broekhoff TF; Sweegers CCG; Krijkamp EM; Mantel-Teeuwisse AK; Leufkens HGM; Goettsch WG; Vreman RA
    Value Health; 2021 Jun; 24(6):759-769. PubMed ID: 34119073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budget Impact Analysis of Nusinersen for Spinal Muscular Atrophy in China.
    Duan C; Ai D; Xu Q; Sui B; Zhao K
    Value Health Reg Issues; 2023 Mar; 34():9-13. PubMed ID: 36343513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US.
    Thokala P; Stevenson M; Kumar VM; Ren S; Ellis AG; Chapman RH
    Cost Eff Resour Alloc; 2020; 18():41. PubMed ID: 33041673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel.
    Facey KM; Espin J; Kent E; Link A; Nicod E; O'Leary A; Xoxi E; van de Vijver I; Zaremba A; Benisheva T; Vagoras A; Upadhyaya S
    Pharmacoeconomics; 2021 Sep; 39(9):1021-1044. PubMed ID: 34231135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis.
    Shih ST; Farrar MA; Wiley V; Chambers G
    J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1296-1304. PubMed ID: 34321343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to Value Orphan Drugs? A Review of European Value Assessment Frameworks.
    Blonda A; Denier Y; Huys I; Simoens S
    Front Pharmacol; 2021; 12():631527. PubMed ID: 34054519
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular Atrophy.
    Jalali A; Rothwell E; Botkin JR; Anderson RA; Butterfield RJ; Nelson RE
    J Pediatr; 2020 Dec; 227():274-280.e2. PubMed ID: 32659229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Examining the impact of different country processes for appraising rare disease treatments: a case study analysis.
    Whittal A; Nicod E; Drummond M; Facey K
    Int J Technol Assess Health Care; 2021 May; 37(1):e65. PubMed ID: 34044899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Onasemnogene Abeparvovec Compared With Nusinersen and Risdiplam in Patients With Spinal Muscular Atrophy Type 1 in Brazil: Custo-Efetividade do Onasemnogeno Abeparvoveque (AVXS-101) em Comparação ao Nusinersena e Risdiplam em Pacientes com Atrofia Muscular Espinhal Tipo 1 no Brasil.
    Fernandes BD; D'Athayde Rodrigues F; Cardoso Cirilo HN; Borges SS; Krug BC; Probst LF; Zimmermann I
    Value Health Reg Issues; 2024 Mar; 40():108-117. PubMed ID: 38181723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
    Buyukkaramikli NC; Wigfield P; Hoang MT
    Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HTA decision-making for drugs for rare diseases: comparison of processes across countries.
    Stafinski T; Glennie J; Young A; Menon D
    Orphanet J Rare Dis; 2022 Jul; 17(1):258. PubMed ID: 35804398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The reimbursement for expensive medicines: stakeholder perspectives on the SMA medicine nusinersen and the Dutch Coverage Lock policy.
    Scheijmans FEV; Zomers ML; Fadaei S; Onrust MR; van der Graaf R; Delden JJMV; van der Pol WL; van Thiel GJMW
    BMC Health Serv Res; 2022 Nov; 22(1):1320. PubMed ID: 36333803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
    Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
    Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do Health Technology Assessment organisations consider manufacturers' costs in relation to drug price? A study of reimbursement reports.
    Enzing JJ; Knies S; Engel J; IJzerman MJ; Sander B; Vreman R; Boer B; Brouwer WBF
    Cost Eff Resour Alloc; 2022 Aug; 20(1):46. PubMed ID: 36045377
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.